This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
by Zacks Equity Research
The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access
Ekso Bionics (EKSO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and 7.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices
by Zacks Equity Research
Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.
All You Need to Know About Ekso Bionics (EKSO) Rating Upgrade to Buy
by Zacks Equity Research
Ekso Bionics (EKSO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -100% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Ekso Bionics (EKSO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Best Momentum Stocks to Buy for January 31st
by Zacks Equity Research
ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.
New Strong Buy Stocks for January 31st
by Zacks Equity Research
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 22.58% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -10.71% and 8.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -37.50% and 7.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 19.44% and 1.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Ekso Bionics (EKSO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 12.20% and 19.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 10.04% and 8.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 8% and 1.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 32.00% and 18.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -4.00% and 3.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Ekso Bionics (EKSO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Ekso Bionics (EKSO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 27th
by Zacks Equity Research
AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021
Moving Average Crossover Alert: Ekso Bionics (EKSO)
by Zacks Equity Research
Ekso Bionics (EKSO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
New Strong Sell Stocks for May 5th
by Zacks Equity Research
BLKB, CTXS, EKSO, FHI, and GCI have been added to the Zacks Rank #5 (Strong Sell) List on May 5, 2021
Will Ekso Bionics (EKSO) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Ekso Bionics (EKSO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ekso Bionics (EKSO) Surges 9.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ekso Bionics (EKSO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.